Adding empagliflozin to baseline T2D therapies reduces CV and renal risk

  • Inzucchi SE & al.
  • Diabetes Obes Metab
  • 2 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding empagliflozin to a range of blood glucose-lowering regimens for type 2 diabetes (T2D) reduces risk for major adverse cardiovascular events (MACE), heart failure hospitalisation, and chronic kidney disease progression.

Why this matters

  • Previously described cardiovascular (CV) and renal benefits of empagliflozin, a potent and selective sodium-glucose cotransporter 2 inhibitor, do not differ depending on a patient's baseline glucose-lowering therapy.

Study design

  • Researchers in this phase 3 clinical trial studied patients with T2D with established CV disease treated with metformin, sulfonylurea, or insulin alone or in combination (N=7020; 71.5% men; mean age, 63.1±8.6 years), randomly assigning them to receive daily empagliflozin 10 mg, empagliflozin 25 mg, or placebo.
  • Funding: Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company.

Key results

  • Empagliflozin reduced risks for CV death, heart failure hospitalisation, 3-point MACE, and all-cause mortality vs placebo regardless of metformin, sulfonylurea, or insulin use at baseline (P>.05).
  • Empagliflozin reduced the risks for incident or worsening nephropathy vs placebo regardless of sulfonylurea or insulin use at baseline (Pinteraction>.05).
  • Nephropathy risk was lower for patients not using vs using metformin at baseline (HR, 0.47 vs HR, 0.68; Pinteraction=.01).

Limitations

  • The trial was not specifically designed or powered for subgroup analysis by baseline therapy.